ILMN Stock Recent News
ILMN LATEST HEADLINES
Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday.
Illumina, Inc. (NASDAQ:ILMN ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Ankur Dhingra - Chief Financial Officer Brian Blanchett - VP of Finance & Treasurer and Interim Head of Investor Relations Jacob Thaysen - CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Eve Burstein - Sanford C. Bernstein & Co., LLC.
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Illumina (ILMN) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.36 per share a year ago.
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025 GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025 Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025 For fiscal year 2025, we now expect: Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previously Non-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previously Non-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This includes a benefit of approximately 10 cents from recently passed legislation that allows U.S. based R&D spend to be tax-deductible In the quarter, repurchased approximately 4.5 million shares of Illumina stock for $380 million at an average price of $84.66 per share Entered into a definitive agreem
Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing SAN DIEGO , July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial eligibility.
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.